JP2024178159A5 - - Google Patents
Info
- Publication number
- JP2024178159A5 JP2024178159A5 JP2024135623A JP2024135623A JP2024178159A5 JP 2024178159 A5 JP2024178159 A5 JP 2024178159A5 JP 2024135623 A JP2024135623 A JP 2024135623A JP 2024135623 A JP2024135623 A JP 2024135623A JP 2024178159 A5 JP2024178159 A5 JP 2024178159A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- composition according
- approximately
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734649P | 2018-09-21 | 2018-09-21 | |
| US62/734,649 | 2018-09-21 | ||
| PCT/US2019/052161 WO2020061458A1 (en) | 2018-09-21 | 2019-09-20 | Methods of treating cancer |
| JP2021540786A JP2022501441A (ja) | 2018-09-21 | 2019-09-20 | 癌を治療する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540786A Division JP2022501441A (ja) | 2018-09-21 | 2019-09-20 | 癌を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024178159A JP2024178159A (ja) | 2024-12-24 |
| JP2024178159A5 true JP2024178159A5 (enExample) | 2026-03-25 |
Family
ID=69887889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540786A Withdrawn JP2022501441A (ja) | 2018-09-21 | 2019-09-20 | 癌を治療する方法 |
| JP2024135623A Pending JP2024178159A (ja) | 2018-09-21 | 2024-08-15 | 癌を治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540786A Withdrawn JP2022501441A (ja) | 2018-09-21 | 2019-09-20 | 癌を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220125957A1 (enExample) |
| EP (1) | EP3852816A4 (enExample) |
| JP (2) | JP2022501441A (enExample) |
| KR (1) | KR20210095620A (enExample) |
| CN (4) | CN121338051A (enExample) |
| AU (2) | AU2019345320B2 (enExample) |
| CA (1) | CA3112806A1 (enExample) |
| IL (2) | IL281600B2 (enExample) |
| WO (1) | WO2020061458A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015073678A1 (en) | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| MX2020010813A (es) | 2018-04-17 | 2021-01-08 | Endocyte Inc | Metodos de tratamiento de cancer. |
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| US11129912B1 (en) | 2020-07-13 | 2021-09-28 | POINT Biopharma Inc. | Radiopharmaceutical and methods |
| JP2023539990A (ja) | 2020-07-13 | 2023-09-21 | ポイント バイオファーマ インコーポレイテッド | 放射性薬剤および方法 |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| AU2014336638C1 (en) * | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| IL237525A (en) * | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen with a radioactive isotope |
| EP3400229B1 (en) * | 2016-01-10 | 2024-03-06 | Provincial Health Services Authority | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| US10980901B2 (en) * | 2016-12-15 | 2021-04-20 | The European Atomic Energy Community (Euratom), Represented By The European Commission | Treatment of PMSA expressing cancers |
| DK3498308T3 (da) * | 2017-12-13 | 2025-01-02 | Sciencons AS | Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid |
-
2019
- 2019-09-20 AU AU2019345320A patent/AU2019345320B2/en active Active
- 2019-09-20 KR KR1020217011840A patent/KR20210095620A/ko not_active Ceased
- 2019-09-20 CA CA3112806A patent/CA3112806A1/en active Pending
- 2019-09-20 IL IL281600A patent/IL281600B2/en unknown
- 2019-09-20 CN CN202510991492.3A patent/CN121338051A/zh active Pending
- 2019-09-20 EP EP19863079.0A patent/EP3852816A4/en active Pending
- 2019-09-20 JP JP2021540786A patent/JP2022501441A/ja not_active Withdrawn
- 2019-09-20 CN CN201980077048.3A patent/CN113164631A/zh active Pending
- 2019-09-20 WO PCT/US2019/052161 patent/WO2020061458A1/en not_active Ceased
- 2019-09-20 CN CN202510991495.7A patent/CN121130116A/zh active Pending
- 2019-09-20 US US17/277,803 patent/US20220125957A1/en active Pending
- 2019-09-20 CN CN202510991493.8A patent/CN121154858A/zh active Pending
-
2024
- 2024-08-15 JP JP2024135623A patent/JP2024178159A/ja active Pending
-
2025
- 2025-10-15 IL IL323981A patent/IL323981A/en unknown
-
2026
- 2026-03-11 AU AU2026201845A patent/AU2026201845A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501441A5 (enExample) | ||
| Nilsson et al. | Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases | |
| Nagaraju et al. | Cyclooxygenase‐2 in gastrointestinal malignancies | |
| JP2023514333A5 (enExample) | ||
| Stark et al. | Pancreatic ductal adenocarcinoma | |
| JP2021502415A5 (enExample) | ||
| JP2021514395A5 (enExample) | ||
| Howard | Pancreatic adenocarcinoma | |
| JP2021510697A5 (enExample) | ||
| Hsieh et al. | Enhanced antitumour response of gold nanostar-mediated photothermal therapy in combination with immunotherapy in a mouse model of colon carcinoma: Cellular and Molecular Biology | |
| JP2019527740A5 (enExample) | ||
| Zhang et al. | 18F-FAPI-42 PET/CT enhances the diagnostic efficacy for peritoneal metastasis of colorectal cancer and guides treatment decisions: an original retrospective study | |
| CA2483826A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| Forman et al. | Localization of a metastatic adrenal carcinoma using 131I-19-iodocholesterol | |
| Neves et al. | Extended survival after complete pathological response in metastatic pancreatic ductal adenocarcinoma following induction chemotherapy, chemoradiotherapy, and a novel immunotherapy agent, IMM-101 | |
| RU2021111125A (ru) | Способы лечения рака | |
| Liu et al. | Case report: A case study of neoadjuvant immunochemotherapy for locally advanced esophageal squamous carcinoma | |
| Parida et al. | Incidentally detected penile metastases in a patient of carcinoma urinary bladder on follow-up FDG PET/CT | |
| Iyer et al. | Buccal mucosal metastasis of renal cell carcinoma: a case report and review of literature | |
| Li et al. | Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study | |
| Massaro et al. | Microbiome dysbiosis and KRAS-driven tumorigenesis in pancreatic cancer: implications for immune checkpoint inhibitors efficacy | |
| Valdés | Correlation between symptoms and survival in patients with renal cell carcinoma | |
| Hartung et al. | New approaches to adjuvant therapy of colorectal carcinoma including current German activities | |
| RU2492855C2 (ru) | Способ комбинированного лечения немелкоклеточного рака легкого ii и iii стадии с пред- и послеоперационной химиотерапией | |
| Narayanan et al. | Polypoid Large Intestinal Involvement of Metastatic Castrate-Resistant Prostate Cancer: A Case Report |